This scientific talk presents how the iLite® Reporter Cell Platform for the assessment of anti-AAV NAbs is a novel tool for rapid and reliable detection of an inhibitory humoral response to the viral vector and was developed to be used in clinical applications.
The efficacy of gene therapies using recombinant AAV can be limited by an antibody-mediated immunity against the virus. AAV infections, potentially occurring in early childhood, may result in a pre-existing immunity to one or more AAV serotypes. Here we present a novel two-component iLite® reporter cell system for the detection and quantification of neutralizing antibodies against AAV vectors. This assay allows for reliable assessment of anti-AAV antibodies in clinical applications